참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | Hydrochloric Acid | HCID 313 | — |
| 반응물 | tert-Butyl methyl ether | HCID 15413 | — |
| 반응물 | Itraconazole | HCID 55283 | — |
| 반응물 | L-Tartaric acid | HCID 444305 | — |
| 용매 | 1,4-Dioxane | HCID 31275 | — |
| 생성물 | 2,3-Dihydroxybutanedioic Acid | HCID 875 | — |
| 생성물 | Itraconazole hydrochloride | HCID 11434139 | — |
반응 단계
Co-crystals of itraconazole HCl and tartaric acid were prepared. Approximately 212.7 mg of L-tartaric acid and 118 microL of 37% HCl were dissolved in 25 mL of hot dioxane. This solution was added to 1.0 g of cis-itraconazole dissolved in 50 mL of hot dioxane with stirring. The mixture was heated until a clear solution formed and was then allowed to cool to room temperature. Upon cooling, 50 mL tert-butyl methyl ether was added and the crystals were harvested by vacuum filtration on a Buchner funnel with #4 Whatman filter paper. The crystals were washed 3 times with 5 mL aliquots of cold tert-butyl methyl ether and left to air dry. Approximately 573 mg of a crystalline form of cis-itraconazole HCl-tartaric acid (1:1:0.5) co-crystal were obtained. (See FIGS. 20 and 21)
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US07927613B2 |
|---|
| 출처 데이터셋 | uspto-grants-2011_04 |
|---|
| ORD ID | ord-e7ffca1b8a794dc2afbb6d3f2ae1018f |
|---|
| 출처 메모 | uspto-grants-2011_04 |
|---|